



CARLSONInvestments

Monthly report

CARLSON INVESTMENTS SE

For the period from 01.08.2022 to 31.08.2022

Board of Directors of CARLSON INVESTMENTS SE
with its registered office in Warsaw
(hereinafter referred to as the Issuer, the
Company) provides the enclosed monthly
report
For August 2022.

Legal basis:

Legal basis: para. 16 of the Appendix
to Resolution No. 293/2010 of the
Management Board of the Warsaw Stock
Exchange of 31.03.2010.

"Good Practices of Companies Listed on
NewConnect".

Persons representing the Issuer

Aleksander Gruszczynski - Chairman of the Board

Warsaw, September 14, 2022



Table of contents

1. Description of trends and events in the Issuer's environment,
2. List of reports published by the Issuer in August 2022. ,
3. Information on the achievement of issue objectives,
4. Investor Calendar

1. DESCRIPTION OF TRENDS AND EVENTS IN THE ISSUER'S ENVIRONMENT

As of August 2022, the Company's day-to-day operations, based on the provision of consulting services and the establishment and optimal management of the Issuer's Group entities, focused on asset growth in the areas of: IT, DeepTech, SaaS, FinTech, MedTech, CleanTech, IoT, Augmented Reality, Artificial Intelligence, Nanotechnology, Nanorobotics, Machine Learning, Biotechnology, Medicine, Education, Pharmacology, Consumer Food, as well as industries related to the Issuer's historical business, i.e.. energy-efficient construction.

On August 4, 2022, a letter of intent was signed between the Issuer and Crispr Stem & Therapeutics Ltd.(CST) for a potential investment. CST is an Israeli startup that is developing a patented cardioprotective stem cell protocol based on CRISPR technology to reduce heart damage after acute myocardial infarction and chronic heart failure. CST was founded by world-renowned specialist Dr. Dalia El-Ani, who has more than 25 years of experience in conducting research projects in cardiovascular and neural sciences, confirmed by a number of awards. The company's technology will use CRISPR to genetically modify a patient's own stem cells, which are then processed by Crispr Stem & Therapeutics' protocol and implanted into a patient with acute ischemic heart disease. Crispr Stem & Therapeutics has received recognition from the Israel Innovation Authority (Tnufa funding) and the European Commission with two Seals of Excellence.

In addition, in August, the Issuer began a partnership with Monaco Foundry Global S.A., based in Monaco. Monaco Foundry Global S.A. is developing a proprietary application to evaluate and support start-ups on their path to success. Owned and developed, the due diligence protocol aims to connect accredited startups and investors. The issuer will be the first publicly listed venture capital firm using the platform to evaluate all new investments and its current investment portfolio. Through the platform, the Company will have the ability to continuously evaluate its potential and portfolio companies to identify strengths and weaknesses in various areas, such as EQ (emotional intelligence), management, IP (intellectual property), and legal and financial documentation. The issuer also does not rule out capital involvement in Monaco Foundry.

OceanTech Acquisitions, in which Carlson Investments ASI SA (a subsidiary of Carlson Investments SE) holds shares, has entered into an agreement to acquire Captura Biopharma. The boards of both companies expect the deal to be finalized in Q4 2022. When the deal is finalized, OceanTech Acquisitions will change its name to Captura Biopharma Holdings Inc. and plans to remain listed on New York's NASDAQ where it is currently listed. The combined company will have a market capitalization of approximately \$224.3 million, assuming a share price of \$10 and no redemptions reported by existing OceanTech shareholders. This gives a minimum 100% return on investment for Carlson Investments over a 12-month period. Captura Biopharma, is a biotechnology company developing and commercializing a drug for the treatment of internal contamination with transuranic radiation and heavy metals (including lead), which comes in the form of a tasteless oral powder. The agent can be dissolved in water and stored in ambulances and hospitals, among others

During the month under review, the Issuer continued its formalized cooperation with Carlson Ventures International Limited (CVI) and partner entity CARLSON EVIG ALFA VC Fund to support investments from the Fund's portfolio, which funds start-ups under the BRIDGE Alpha program. As of August 2022, CARLSON ASI EVIG ALFA Fund's portfolio companies are continuing their started projects as planned.

In August, CARLSON EVIG ALFA VC Fund added a project to its portfolio companies:



www.playstrict.com

SaaS platform for mobile studio GameDevs using AI algorithms for planning, softlaunch optimization, LiveOps and marketing campaigns.

In addition, the CARLSON ASI EVIG ALFA Fund has financially supported the NTW project. The goal of the project's originators is to develop a backyard RES installation that does not require additional permits and achieves optimal energy yields in low-speed winds. Ultimately, the installation will consist of a power converter, a step turbine, a wing and a dedicated roof structure. In addition, it is envisaged to develop an algorithm making a forecast of the payback time, as well as functionality allowing the prosumer to monitor the energy yield on an ongoing basis

2. SUMMARY OF REPORTS PUBLISHED BY THE ISSUER IN JUNE 2022,

During the reporting period (i.e., August 2022), the Company published the following reports via ESPI:

13-08-2022 | Current Report No. 19/2022 - June 2022 monthly report and July 2022 monthly report.
16-08-2022 | Quarterly Report No. 19/2022 - interim report for the second quarter of 2022

During the reporting period (i.e., August 2022), the Company published the following reports via ESPI:

04-08-2022 | Current Report No. 16/2022 - Signing of a letter of intent
08-08-2022 | Current report no. 17/2022 - Start of cooperation

3. INFORMATION ON THE ACHIEVEMENT OF THE ISSUE OBJECTIVES,

During the period covered by the report, the Company did not meet its issuance targets.

4. INVESTOR'S CALENDAR

By October 14, 2022, the Issuer's Management Board will make public the contents of the monthly report for September 2022.



CARLSON Investments

